New drug showdown: can it outperform standard pills to keep advanced throat cancer at bay?

This study aims to see if a new intravenous drug, Becotatug Vedotin, works better than the standard oral chemotherapy (capecitabine) at preventing cancer from coming back in people with high-risk, advanced nasopharyngeal carcinoma (a type of throat cancer). It will involve about 218 patients who have already finished their initial chemoradiotherapy. Participants will be randomly assigned to receive either the new drug for three cycles or the standard pills for one year, and researchers will track which group stays cancer-free longer.